ARDX– Ardelyx, Inc is a clinical stage bio-pharmaceutical company which develops therapeutic drugs for the treatment of Gastro-Intestinal and Cardio – Renal diseases. ARDX was given a “Buy”rating from Ladenburg Thalmann, and may be bullish today.
ARDX – Ardelyx, Inc.
|Fundamentals||Previously closed at||7.77|
|Analysts opinion||Out of the 4 wall street analysts covering the stock, all 4 have given this stock a “Strong Buy” rating. For the most recent quarter, Ardelyx reported a surprise factor of 12.16%. The Analyst consensus price target for the stock is $19.|
|Anapanor, Ardelyx’s lead investigational drug expected to cure IBS-C (Irritable bowel syndrome with constipation) is currently under Phase 3 clinical studies. According to study, there are approx. 4.4 million Americans, 6.6 million Europeans, and 3.4 Japanese suffering from IBS-C- a huge potential market for Anapanor.|
|Sentiments||One of Ardelyx’s Director Gordon Ringold purchased 15,000 shares of the firm at $7.64 – $7.86 per share. This may cause further bullish investor sentiments|
|Social Media Pulse||The stock has 100% lower chatter than usual.|